Tezomib 2 mg contains bortezomib, a targeted anti-cancer medicine classified as a proteasome inhibitor. It is primarily used in the treatment of certain blood cancers such as multiple myeloma and mantle cell lymphoma. Bortezomib works at the cellular level by interfering with the way cancer cells process proteins, helping to stop their growth and triggering cell death.

Tezomib is administered by injection, usually under the skin or into a vein, and forms a core part of modern therapy regimens for patients with relapsed or newly diagnosed myeloma.

Mechanism of Action

Bortezomib works by inhibiting the 26S proteasome, a system inside cells responsible for breaking down and recycling proteins. In cancer cells, this inhibition leads to a build-up of unwanted or damaged proteins, causing stress within the cell.

This stress disrupts several important pathways that cancer cells rely on for survival, eventually leading to programmed cell death or apoptosis.

Because myeloma cells are more dependent on proteasome activity than normal cells, bortezomib is particularly effective in targeting and killing these cancerous cells without harming too many healthy ones.

Uses

Tezomib is commonly used in the treatment of:

• Multiple myeloma, including newly diagnosed or relapsed cases, often in combination with other drugs like lenalidomide or dexamethasone

• Mantle cell lymphoma, especially in patients who have already received prior treatment

  Adverse Effects

  While bortezomib is a powerful cancer therapy, it may also cause side effects. These can vary depending on the patient’s overall condition and whether the drug is given alone or with other treatments.

  Common Side Effects

  • Tiredness or weakness

  • Nausea and vomiting

  • Diarrhea or constipation

  • Peripheral neuropathy, presenting as tingling, numbness, or pain in the hands and feet

  • Loss of appetite